<DOC>
	<DOC>NCT00875875</DOC>
	<brief_summary>The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR 2. a single 600 mg dose of rifaximin daily for 3 days.</brief_summary>
	<brief_title>Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>passage of 3 or more unformed stools in 24 hours plus an additional symptom of enteric disease such as abdominal cramps, nausea, vomiting, or fever; and investigator verification that an unformed stool has been submitted. is &gt; 18 years of age has diarrhea (at least three unformed stools in 24 hrs) plus at least one additional sign or symptom of enteric illness has acute diarrhea less than 1 week's duration willingness to provide a diarrhea stool sample willingness to keep a daily diary for 5 days signed informed consent fever or bloody diarrhea has taken predictably effective antibiotics in the past week (e.g. quinolones, TMP/SMX, azalide or doxycycline) is pregnant now, likely to become pregnant, or breastfeeding has duration of diarrhea of greater than 1 weeks is allergic to Rifampin or Rifaximin has a history of significant underlying enteric, pulmonary, cardiac, renal disease, or any CNS disorder is more than moderately dehydrated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Diarrhea, travelers</keyword>
	<keyword>Acute travelers' diarrhea</keyword>
</DOC>